What’s new
Oxford Cancer Biomarkers welcomes major investment partnership with MGMED, Inc.
Investment will drive rapid uptake of OCB’s cancer tests and expand its development pipeline Oxford Cancer Biomarkers Ltd (OCB), the
Oxford Cancer Biomarkers announces strategic collaboration with My-BioMed Biotechnology Co. Ltd
Collaboration will allow OCB’s suite of precision oncology In Vitro Diagnostic tests to be rolled out across the People’s Republic
Chemotherapy side effect predicting Oxford biotech firm secures CE marking
Oxford Cancer Biomarker’s ColoTox test will now be available to UK patients considering chemotherapy Oxford, UK, 14th March 2017 –
Oxford Cancer Biomarkers announces ColoTox test for predicting cancer chemotherapy toxicity enters clinical studies
First patient enrolled in clinical utility study Oxford, UK, 9th November 2016 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company
Oxford Cancer Biomarkers appoints Kathryn Kuhne as its Commercial and Marketing Director
Oxford, UK, 10 June 2016 Oxford Cancer Biomarkers has appointed Kathryn Kuhne as Commercial and Marketing Director, a key growth
Oxford Cancer Biomarkers announces Partnership with Room4
Oxford, UK, 18 January 2016 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be
Oxford Cancer Biomarkers announces new investment to commercialise its colorectal cancer diagnostic tests
Oxford, UK, 14 December 2015 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be
Oxford Cancer Biomarkers announces UK patent filed
Oxford, UK, 07 Sep 2015 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be